Literature DB >> 2154381

Intraphagocytic activity of erythromycin, roxithromycin and azithromycin.

D Milatovic1.   

Abstract

The intraphagocytic activity of erythromycin, roxithromycin and azithromycin against phagocytosed Staphylococcus aureus was compared. Erythromycin and roxithromycin both acted bacteriostatically at concentrations corresponding to 10 X MIC. Azithromycin, however, did not prevent intracellular proliferation of the staphylococci. On comparison of the pH dependency of the antibacterial activity of the three drugs, azithromycin was found to be inactivated earlier in an acidic milieu.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2154381     DOI： 10.1007/BF01969530

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  12 in total

1.  Antibiotic killing of Legionella.

Authors:  F G Rodgers; T S Elliott
Journal:  Lancet       Date:  1984-03-24       Impact factor: 79.321

2.  Effect of subinhibitory antibiotic concentrations on the phagocytosis of Staphylococcus aureus.

Authors:  D Milatović
Journal:  Eur J Clin Microbiol       Date:  1982-04       Impact factor: 3.267

3.  Intracellular multiplication of Legionnaires' disease bacteria (Legionella pneumophila) in human monocytes is reversibly inhibited by erythromycin and rifampin.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

4.  Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor against Mycobacterium avium complex.

Authors:  L E Bermudez; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

5.  Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells.

Authors:  M B Carlier; A Zenebergh; P M Tulkens
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

6.  An in-vitro comparison of the intraphagocytic bioactivity of erythromycin and roxithromycin.

Authors:  R Anderson; C E Van Rensburg; G Jooné; P T Lukey
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

7.  Antibiotic action on phagocytosed bacteria measured by a new method for determining viable bacteria.

Authors:  K Vosbeck; P R James; W Zimmermann
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

8.  Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents.

Authors:  J L Vildé; E Dournon; P Rajagopalan
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

9.  Entry of roxithromycin (RU 965), imipenem, cefotaxime, trimethoprim, and metronidazole into human polymorphonuclear leukocytes.

Authors:  W L Hand; N King-Thompson; J W Holman
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

10.  In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii.

Authors:  H R Chang; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191
View more
  9 in total

1.  Intracellular bactericidal activity of fosfomycin against staphylococci: a comparison with other antibiotics.

Authors:  M Trautmann; C Meincke; K Vogt; M Ruhnke; A M Lajous-Petter
Journal:  Infection       Date:  1992 Nov-Dec       Impact factor: 3.553

2.  Synergistic effect of azithromycin on the phagocytic killing of Staphylococcus aureus by human polymorphonuclear leukocytes.

Authors:  I Herrera-Insúa; P Pérez; C Ramos; P Martínez; M L Gómez-Lus; J Prieto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

Review 3.  Phagocyte uptake and transport of azithromycin.

Authors:  P J McDonald; H Pruul
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

Review 4.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

5.  In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence.

Authors:  M Bonnet; P Van der Auwera
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

6.  Uptake of azithromycin by human monocytes and enhanced intracellular antibacterial activity against Staphylococcus aureus.

Authors:  A P Meyer; C Bril-Bazuin; H Mattie; P J van den Broek
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

7.  Intracellular activity of azithromycin against bacterial enteric pathogens.

Authors:  R M Rakita; K Jacques-Palaz; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

8.  Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.

Authors:  Cristina Seral; Françoise Van Bambeke; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

9.  Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.

Authors:  Sreedhar Subramanian; Carol L Roberts; C Anthony Hart; Helen M Martin; Steve W Edwards; Jonathan M Rhodes; Barry J Campbell
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.